Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report issued on Wednesday. The brokerage set a “hold” rating on the stock.

Oncternal Therapeutics Price Performance

Shares of Oncternal Therapeutics stock opened at $0.53 on Wednesday. Oncternal Therapeutics has a 1 year low of $0.53 and a 1 year high of $13.14. The company has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. The business has a 50 day moving average price of $0.66 and a 200 day moving average price of $2.58.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.